14682 Federal Register / Vol. 62, No. 59 / Thursday, March 27, 1997 / Notices

or protests should be filed on or before

the comment date. Protests will be

considered by the Commission in

determining the appropriate action to be

taken, but will not serve to make

protestants parties to the proceeding.

Any person wishing to become a party

must file a motion to intervene. Copies

of this filing are on file with the

Commission and are available for public

inspection.

Linwood A. Watson, Jr.,

Acting Secretary.

[FR Doc. 97–7757 Filed 3–26–97; 8:45 am]

BILLING CODE 6717–01–P

ENVIRONMENTAL PROTECTION

AGENCY

[FRL–5803–8]

National Drinking Water Advisory

Council Consumer Confidence

Working Group; Notice of Open

Meeting

Under Section 10(a)(2) of Public Law

92–423, ‘‘The Federal Advisory

Committee Act,’’ notice is hereby given

for upcoming meetings of the Consumer

Confidence Working Group of the

National Drinking Water Advisory

Council (established under the Safe

Drinking Water Act, as amended (42

U.S.C. 300f et seq.)), to be held April 3,

1997, from 1:00 p.m. to 5:00 p.m. and

April 4, 1997, from 9:00 a.m. to 5:00

p.m. at the Westin City Center, 1400 M

Street NW, Washington, DC; and May 8,

1997, from 9:00 a.m. to 5:00 p.m. and

May 9, 1997, from 9:00 a.m. to 3:00 p.m.

at the Dupont Plaza Hotel, 1500 New

Hampshire Ave. NW, Washington DC.

The purpose of the meetings is to

discuss drafts of rule language and

attendant documents. The meetings are

open to the public, but seating is

limited. Statements from the public will

be taken at the end of the meeting if

time allows.

For more information, please contact,

Francoise M. Brasier, Designated

Federal Officer, Consumer Confidence

Working Group, U.S. EPA, Office of

Ground Water and Drinking Water 5606,

401 M Street SW, Washington, D.C.

20460. The telephone number is Area

Code 202–260–5668. The e-mail address

is brasier.francoise & epamail.epa.gov.

Dated: March 12, 1997.

Charlene Shaw,

Designated Federal Officer, National Drinking

Water Advisory Council.

[FR Doc. 97–7816 Filed 3–26–97; 8:45 am]

BILLING CODE 6560–50–M

FEDERAL MARITIME COMMISSION

Ocean Freight Forwarder License

Applicants

Notice is hereby given that the

following applicants have filed with the

Federal Maritime Commission

applications for licenses as ocean freight

fowarders pursuant to section 19 of the

Shipping Act of 1984 (46 U.S.C. app.

1718 and 46 CFR 510).

Persons knowing of any reason why

any of the following applicants should

not receive a license are requested to

contact the Office of Freight Forwarders,

Federal Maritime Commission,

Washington, D.C. 10573.

Anchor Shipping and Chartering Co.,

5619 Hazen Street, Houston, TX

77081, Ronny Gene Mollard, Sole

Proprietor

Nick Rendon III International Inc., 139

Mitchell Avenue, Ste. 216, So. San

Francisco, CA 94080, Officer:

Nicholas Rendon III, President

Cargo America Group, Ltd., 4702

Lucerne Valley Road, Lilburn, Georgia

30247, Officers: Troy Abercrombie,

President, Wanda Abercrombie,

President

Dated: March 24, 1997.

Joseph C. Polking,

Secretary.

[FR Doc. 97–7779 Filed 3–26–97; 8:45 am]

BILLING CODE 6730–01–M

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and

Mergers of Bank Holding Companies

The companies listed in this notice

have applied to the Board for approval,

pursuant to the Bank Holding Company

Act of 1956 (12 U.S.C. 1841 et seq.)

(BHC Act), Regulation Y (12 CFR Part

225), and all other applicable statutes

and regulations to become a bank

holding company and/or to acquire the

assets or the ownership of, control of, or

the power to vote shares of a bank or

bank holding company and all of the

banks and nonbanking companies

owned by the bank holding company,

including the companies listed below.

The applications listed below, as well

as other related filings required by the

Board, are available for immediate

inspection at the Federal Reserve Bank

indicated. Once the application has

been accepted for processing, it will also

be available for inspection at the offices

of the Board of Governors. Interested

persons may express their views in

writing on the standards enumerated in

the BHC Act (12 U.S.C. 1842(c)). If the

proposal also involves the acquisition of

a nonbanking company, the review also

includes whether the acquisition of the

nonbanking company complies with the

standards in section 4 of the BHC Act.

Unless otherwise noted, nonbanking

activities will be conducted throughout

the United States.

Unless otherwise noted, comments

regarding each of these applications

must be received at the Reserve Bank

indicated or the offices of the Board of

Governors not later than April 21, 1997.

A. Federal Reserve Bank of New

York (Christopher J. McCurdy, Senior

Vice President) 33 Liberty Street, New

York, New York 10045-0001:

1. BanPonce Corporation, Hato Rey,

Puerto Rico; Poplar International Bank,

Inc., Hato Rey, Puerto Rico; and

BanPonce Financial Corp., Wilmington,

Delaware; to acquire 100 percent of the

voting shares of CBC Bancorp, Ltd.,

Chicago, Illinois, and thereby indirectly

acquire Capitol Bank of Westmont,

Westmont, Illinois, and Capitol Bank

and Trust, Chicago, Illinois.

B. Federal Reserve Bank of Atlanta

(Lois Berthaume, Vice President) 104

Marietta Street, N.W., Atlanta, Georgia

30303-2713:

1. Florida Bancshares, Inc., Dade City,

Florida; to become a bank holding

company by acquiring 100 percent of

the voting shares of First National Bank

of Pasco, Dade City, Florida.

C. Federal Reserve Bank of San

Francisco (Kenneth R. Binning,

Director, Bank Holding Company) 101

Market Street, San Francisco, California

94105-1579

1. Pierce County Bancorp, Tacoma,

Washington; to become a bank holding

company by acquiring 100 percent of

the voting shares of Pierce Commercial

Bank, Tacoma, Washington (in

organization).

Board of Governors of the Federal Reserve

System, March 21, 1997.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 97–7768 Filed 3–26–97; 8:45 am]

BILLING CODE 6210–01F

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 96N–0487]

Agency Information Collection

Activities; Announcement of OMB

Approval

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.
Federal Register / Vol. 62, No. 59 / Thursday, March 27, 1997 / Notices 14683

SUMMARY: The Food and Drug

Administration (FDA) is announcing

that a collection of information entitled

‘‘Current Good Manufacturing Practices

for Blood and Blood Components:

Notification of Consignees Receiving

Blood and Blood Components at

Increased Risk for Transmitting HIV’’

has been approved by the Office of

Management and Budget (OMB) under

the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT:

Margaret R. Wolff, Office of Information

Resources Management (HFA–250),

Food and Drug Administration, 5600

Fishers Lane, rm. 16B–19, Rockville,

MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: In the

Federal Register of December 27, 1996

(61 FR 68268), the agency announced

that the proposed information collection

had been submitted to OMB for review

and clearance under section 3507 of the

Paperwork Reduction Act of 1995 (44

U.S.C. 3507). OMB has now approved

the information collection and has

assigned OMB control number 0910–

0336. The approval expires on February

28, 2000. An agency may not conduct or

sponsor, and a person is not required to

respond to, a collection of information

unless it displays a currently valid OMB

control number.

Dated: March 19, 1997.

William K. Hubbard,

Associate Commissioner for Policy

Coordination.

[FR Doc. 97–7726 Filed 3–26–97; 8:45 am]

BILLING CODE 4160–01–F

Advisory Committees; Notice of

Meetings

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: This notice announces

forthcoming meetings of public advisory

committees of the Food and Drug

Administration (FDA). This notice also

summarizes the procedures for the

meetings and methods by which

interested persons may participate in

open public hearings before FDA’s

advisory committees.

FDA has established an Advisory

Committee Information Hotline (the

hotline) using a voice-mail telephone

system. The hotline provides the public

with access to the most current

information on FDA advisory committee

meetings. The advisory committee

hotline, which will disseminate current

information and information updates,

can be accessed by dialing 1–800–741–

8138 or 301–443–0572. Each advisory

committee is assigned a 5-digit number.

This 5-digit number will appear in each

individual notice of meeting. The

hotline will enable the public to obtain

information about a particular advisory

committee by using the committee’s 5-

digit number. Information in the hotline

is preliminary and may change before a

meeting is actually held. The hotline

will be updated when such changes are

made.

MEETINGS: The following advisory

committee meetings are announced:

Nonprescription Drugs Advisory

Committee

Date, time, and place. April 15, 1997,

8 a.m.; Holiday Inn—Gaithersburg,

Goshen Room, Two Montgomery Village

Ave., Gaithersburg, MD.

Type of meeting and contact person.

Open committee discussion, 8 a.m. to

1:30 p.m.; open public hearing 1:30 p.m.

to 2:30 p.m., unless public participation

does not last that long; open committee

discussion, 2:30 p.m. to 5 p.m.; closed

committee deliberations, 5 p.m. to 6

p.m.; Andrea G. Neal, Center for Drug

Evaluation and Research (HFD–21),

Food and Drug Administration, 5600

Fishers Lane, Rockville, MD 20857,

301–443–5455, or FDA Advisory

Committee Information Hotline, 1–800–

741–8138 (301–443–0572 in the

Washington, DC area), Nonprescription

Drugs Advisory Committee, code 12541.

Please call the hotline for information

concerning any possible changes.

General function of the committee.

The committee reviews and evaluates

available data concerning the safety and

effectiveness of over-the-counter

(nonprescription) human drug products

for use in the treatment of a broad

spectrum of human symptoms and

diseases.

Agenda—Open public hearing.

Interested persons may present data,

information, or views, orally or in

writing, on issues pending before the

committee. Those desiring to make

formal presentations should notify the

contact person before April 1, 1997, and

submit a brief statement of the general

nature of the evidence or arguments

they wish to present, the names and

addresses of proposed participants, and

an indication of the approximate time

required to make their comments.

Open committee discussion. The

committee will discuss a possible

association between vaginal douching

and adverse consequences. FDA is

aware of a number of case-control

epidemiologic studies in the literature

that suggest a possible association

between vaginal douching and several

conditions, such as pelvic inflammatory

disease, ectopic pregnancy, and cervical

cancer (letter from D. Bowen, FDA, to R.

W. Soller, Nonprescription Drug

Manufacturers Association, LET 105,

Docket No. 75N–0183, Dockets

Management Branch). The committee’s

discussion will include issues relating

to behavioral, epidemiological, and

microbiological aspects of vaginal

douching. Regulatory issues related to

over-the-counter vaginal-douche drugs,

cosmetics, and devices (douching

equipment) will also be addressed.

Closed committee deliberations. The

committee will review trade secret and/

or confidential commercial information

relevant to pending investigational new

drugs applications (IND’s) or new drug

applications (NDA’s). This portion of

the meeting will be closed to permit

discussion of this information. (5 U.S.C.

552b (c)(4)).

Dermatologic and Ophthalmic Drugs

Advisory Committee

Date, time, and place. April 17 and

18, 1997, 8:30 a.m., Holiday Inn—

Gaithersburg, Grand Ballroom, Two

Montgomery Village Ave., Gaithersburg,

MD.

Type of meeting and contact person.

Open public hearing, April 17, 1997,

8:30 a.m. to 9:30 a.m., unless public

participation does not last that long;

open committee discussion, 9:30 a.m. to

5:30 p.m.; closed presentation of data,

April 18, 1997, 8:30 a.m. to 11 a.m.;

closed committee deliberations, 11 a.m.

to 1 p.m.; Tracy Riley or Angie

Whitacre, Center for Drug Evaluation

and Research (HFD–21), Food and Drug

Administration, 5600 Fishers Lane,

Rockville, MD 20857, 301–443–5455, or

FDA Advisory Committee Information

Hotline, 1–800–741–8138 (301–443–

0572 in the Washington, DC area),

Dermatologic and Ophthalmic Drugs

Advisory Committee, code 12534.

Please call the hotline for information

concerning any possible changes.

General function of the committee.

The committee reviews and evaluates

available data concerning the safety and

effectiveness of marketed and

investigational human drug products for

use in the treatment of dermatologic and

ophthalmic disorders.

Agenda—Open public hearing.

Interested persons may present data,

information, or views, orally or in

writing, on issues pending before the

committee. Those desiring to make

formal presentations should notify the

contact person before April 11, 1997,

and submit a brief statement of the

general nature of the evidence or

arguments they wish to present, the

names and addresses of proposed

participants, and an indication of the